NASD · Healthcare · Biotechnology · USA
Dianthus Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody targeting C1s complement protein administered via self-administered subcutaneous injections. The company also develops DNTH212, a bifunctional fusion protein targeting plasmacytoid dendritic cells and B cell function for autoimmune indications.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Dianthus Therapeutics Inc stock.
Overvalued: intrinsic value $6.60 per share, market price $86.98, margin of safety -1217.0% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $6.60; the price of $86.98 is 1217% above that value.
17 more funds hold it; the full list is part of the paid plan.
110 more in this industry show a wider margin of safety.
DNTH is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.60; the price of $86.98 is 1217% above that value.
$6.60 per share (as of the 2026-11-17 close), against a market price of $86.98. That is a margin of safety of -1217.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.